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Chronic kidney disease (CKD) affects approximately 10% of the world’s adult population; it is within the top 20
causes of death worldwide, and its impact on patients and their families can be devastating. World Kidney Day and
International Women’s Day in 2018 coincide, thus offering an opportunity to reﬂect on the importance of women’s
health and speciﬁcally their kidney health, on the community, and the next generations, as well as to strive to be more
curious about the unique aspects of kidney disease in women so that we may apply those learnings more broadly.
Girls and women, who make up approximately 50% of the world’s population, are important contributors to society
and their families. Gender differences continue to exist around the world in access to education, medical care, and
participation in clinical studies. Pregnancy is a unique state for women, which not only offers an opportunity for
diagnosis of kidney disease, but also states where acute and chronic kidney diseases may manifest, and which may
impact future generations with respect to kidney health. There are various autoimmune and other conditions that are
more likely to impact women with profound consequences for childbearing, and on the fetus. Women have different
complications on dialysis than men and are more likely to be donors than recipients of kidney transplants. In this
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editorial, we focus on what we do and do not know about women, kidney health, and kidney disease and what we
might learn in the future to improve outcomes worldwide.
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Kidney Health and Women’s Health: A Case for Optimizing Outcomes for
Present and Future Generations
Introduction
Chronic kidney disease (CKD) affects approximately 10% of the world’s adult population: it
is within the top 20 causes of death worldwide (31), and its impact on patients and their
families can be devastating. World Kidney Day and International Women’s Day in 2018
coincide, thus offering an opportunity to reﬂect on the importance of women’ s health and
speciﬁcally their kidney health, on the community, and the next generations, as well as to
strive to be more curious about the unique aspects of kidney disease in women, so that we
may apply those learnings more broadly.
Girls and women, who make up approximately 50% of the world’s population, are
important contributors to society and their families. Besides childbearing, women are
essential in childbearing and contribute to sustaining family and community health. Women
in the 21st century continue to strive for equity in business, commerce, and professional
endeavors, while recognizing that in many situations, equity does not exist. In various
locations around the world, access to education and medical care is not equitable among
men and women; women remain underrepresented in many clinical research studies, thus
limiting the evidence base on which to make recommendations to ensure best outcomes
(Fig. 1).
Fig. 1. Sex differences throughout the continuum of CKD care. SLE: systemic lupus erythematosus; RA: rheumatoid
arthritis; SS: systemic scleroderma; AKI: acute kidney injury; CKD: chronic kidney disease; AI: autoimmune; AVF:
arteriovenous ﬁstula; HD: hemodialysis; KT: kidney transplant
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In this editorial, we focus on what we do and do not know about women’s kidney health
and kidney disease and what we might learn in the future to improve outcomes for all.
What we know and do not know
Pregnancy is a unique challenge and is a major cause of acute kidney injury (AKI)
in women of childbearing age; AKI and preeclampsia (PE) may lead to subsequent
CKD, but the entity of the risk is not completely known (64, 98, 101, 103). CKD has a
negative effect on pregnancy even at very early stages (81, 113). The risks increase with
CKD progression, thus posing potentially challenging ethical issues around conception
and maintenance of pregnancies (4, 81, 113). We know that PE increases the probability
of hypertension and CKD in later years, but we have not evaluated a surveillance or
reno-protective strategy to determine if progressive loss of kidney function can be
attenuated (1, 46, 57, 82).
Speciﬁc systemic conditions like systemic lupus erythematosus (SLE), rheumatoid
arthritis (RA), and systemic scleroderma (SS) are more likely to affect women than men. We
do not know the relative contribution of these acute and chronic conditions on progression to
end-stage renal disease (ESRD) in women.
In CKD cohorts, the prevalence in women is always less than in men, and they have
slower progression to ESRD (44, 53, 70). We do not know why and how much of this is due
to differences in identiﬁcation of kidney impairment, different access to care, or true
difference in disease severity and prevalence.
Women with CKD have a higher cardiovascular risk than women without CKD (106),
but their risk is still lower than that of men with similar degrees of kidney impairment. In
hemodialysis cohorts, there are differences in vascular access types in women versus men,
which may be due to biological or systemic factors. In some locations, there is differential use
of peritoneal and hemodialysis in women and men.
Women are more likely to donate kidneys for transplantation than to receive them. We
do not know if this is because of the differential incidence of CKD in men versus women,
cultural factors, or other reasons.
There remain gender differences in access to care in different regions of the world, and
we do not have data to directly evaluate the extent of these differences, in the poorest parts of
the world in particular.
Pregnancy, PE, pregnancy-induced hypertensive disorders, and fetal health.
The importance of women’s health to present and future kidney health
What we know
PE is the principal cause of AKI and maternal death, particularly in developing countries (74,
103). Pregnancy is the most common cause of AKI in women of childbearing age (56, 57,
100). Several diseases and conditions, besides PE, hypertensive disorders of pregnancy, and
CKD, can lead to pregnancy-related AKI. Causes vary in different regions. Septic abortion
after an illegal procedure is the leading cause of early AKI in countries where legal abortions
are not available, while PE after assisted fertilization is becoming a leading cause in
developed countries (1, 9, 41, 88).
PE and hypertensive disorders of pregnancy occur in 3%–10% of all pregnancies (64,
74, 103); in these disorders, the kidney is the main target of an unbalanced proangiogenic
and antiangiogenic derangements, leading to hypertension, proteinuria, and widespread
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endothelial damage. The incidence of PE, higher in low-middle income countries (possibly
reﬂecting undiagnosed predisposing diseases), peaks at the extremes of reproductive age for
reasons mentioned above (1, 9, 41, 88).
The relationship between kidney and placenta is biunivocal, and the presence of CKD is
a risk factor for PE and hypertensive disorders of pregnancy (Fig. 2). Besides CKD, other
conditions cited as risk factors for PE (diabetes, immunologic diseases, baseline hyperten-
sion, obesity, and metabolic syndrome) are also risk factors for CKD. Given that even minor
alterations of kidney function are present in many of these disorders, the importance of
kidney function is indirectly recognized in the development of PE. Newer deﬁnitions of PE
recognize differences between “placental” and “maternal” causes of PE, based on novel
angiogenic–antiangiogenic markers (72, 112), which may be important for management
during and after pregnancy.
There are long-term effects of PE on both maternal and fetal health, but this remains an
area of active research with many unknowns.
PE is a risk factor for the future development of CKD and ESRD in the mother (64, 98,
101). The reasons are not fully understood; podocyte loss is a hallmark of PE, suggesting
permanent glomerular damage (30). Endotheliosis, which is not only associated with PE but
also found in normal pregnancies, may herald glomerulosclerosis; tubular and vascular
damage may co-exist (96, 108).
Besides maternal risks, PE is associated with intrauterine and perinatal death,
preterm delivery, and restricted intrauterine growth; the latter two are linked to “small
babies” (64, 98, 103). Small babies and preterm babies have highly increased risks of
neurological deﬁcits and postnatal complications, especially sepsis (35, 36, 54, 65, 90).
The risks may be higher in low-income countries, since survival and deﬁcit-free survival
depend on the provision of postnatal intensive care (41, 88). In the long term, small babies
are at risk for the development of diabetes, metabolic syndrome, cardiovascular diseases
(CVDs), and CKD in adulthood (15, 59, 60–62, 75). Since kidney development is
completed in the last phases of pregnancy, delayed, insufﬁcient kidney growth, resulting
in low nephron number is probably the basis of the increased risk of CKD and
hypertension in small for gestational age, and preterm babies (15, 59, 60–62, 75).
Placenta and kidney are highly 
vascularized; filter blood; divide 
compartments; are sophisticated 
metabolic machines
Pregnancy is a precious occasion 
to diagnose CKD.
From the placenta to the kidney
PE may induce permanent kidney damage, via 
AKI, tubular damage, podocyte loss
From the kidney to the placenta
CKD may induce placental dysfunction 
with an increased risk of pre-term 
delivery, hypertensive disorders of 
pregnancy and PE 
Fig. 2. Pregnancy and kidney
function: complex interactions
between two organs, the
kidney and placenta. PE:
preeclampsia; AKI: acute
kidney injury; CKD: chronic
kidney disease
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Pregnancy in CKD, dialysis, and transplantation
What we know
Chronic kidney disease (CKD). CKD is a risk factor for adverse pregnancy outcomes from its
early stages (Table I) (15, 37, 81). The risks increase from CKD stage 1 to CKD stage 5, and
may be higher in glomerular nephropathies, autoimmune diseases, and diabetic nephropathy
(14, 19, 37, 68, 81, 113). Results of pregnancy after kidney donation suggest that reduction of
kidney parenchyma may be associated with a higher risk of PE and hypertensive disorders of
pregnancy (29, 48).
Table I. Adverse pregnancy outcomes in patients with chronic kidney disease and in their offspring
Term Deﬁnition Main issues
Maternal death Death in pregnancy or within
1 week–1 month postpartum
Too rare to be quantiﬁed, at least in highly resourced
settings, where cases are in the setting of severe ﬂares of
immunologic diseases (SLE in primis). Still an issue in
AKI, and in low-resourced countries; not quantiﬁed in
low-resourced countries, where it merges with dialysis
need
CKD progression Decrease in GFR, rise in sCr,
shift to a higher CKD stage
Differently assessed and estimated; may be linked to
obstetric policy (anticipating delivery in the case of
worsening of the kidney function); between 20% and
80% in advanced CKD. Probably not increased in early
CKD stages
Immunologic ﬂares
and neonatal SLE
Flares of immunologic
diseases in pregnancy
Once thought to be increased in pregnancy, particularly
in SLE, and is probably a risk in patients who start
pregnancy with an active disease, or with a recent
ﬂare-up. Deﬁnition of a “safe” zone is not uniformly
agreed; in quiescent, well-controlled diseases do not
appear to be increased with respect to non-pregnant,
carefully matched controls
Transplant rejection Acute rejection in pregnancy Similar to SLE, rejection episodes are not increased with
respect to matched controls; may be an issue in unplanned
pregnancies, in unstable patients
Abortion Fetal loss, before 21–24
gestational weeks
May be increased in CKD, but data are scant. An issue in
immunologic diseases (eventually, but not exclusively
linked to the presence of LLAC) and in diabetic
nephropathy
Stillbirth Delivery of a nonviable
infant, after 21–24
gestational weeks
Probably not increased in early CKD; maybe an issue in
dialysis patients; when not linked to extreme prematurity,
may be speciﬁcally linked to SLE, immunologic diseases,
and diabetic nephropathy
Perinatal death Death within 1 week–1 month
from delivery
Usually a result of extreme prematurity, which bears a risk
of respiratory distress, neonatal sepsis, and cerebral
hemorrhage
Small, very small
baby
A baby weighing <2,500–
1,500 g at birth
Has to be analyzed with respect to gestational age
(Continued)
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Hypertension and proteinuria at baseline are important modulators of pregnancy-related risks;
among the risks, we know that malformations are not increased with respect to the overall
population (out of the context of inherited diseases, such as reﬂux nephropathy, polycystic
kidney disease, or congenital anomalies of the kidney and urinary tract), maternal death is
unusual (in highly resourced countries), while the incidence of preterm delivery and of small
for gestational age babies, intrinsically linked, is increased in stage 1 CKD patients, and rises
with the worsening of kidney function. Similarly, the effect of pregnancy on CKD
progression is not fully understood because of different study designs, obstetric policies,
and duration of follow-up. Overall, short- and long-term decrease in kidney function is
unusual in early CKD, but the risk increases as CKD severity increases (10, 12, 14, 19, 28, 32,
37, 43, 68, 81, 113).
Pregnancy is a potential occasion for the initial diagnosis of CKD. In poorly or
unevenly resourced countries, advanced CKD may be discovered only during pregnancy.
Table I. Adverse pregnancy outcomes in patients with chronic kidney disease and in their offspring (Continued)
Term Deﬁnition Main issues
Preterm, early, and
extremely preterm
Delivery before 37–34 or 28
completed gestational weeks
Increase in risk of preterm and early preterm delivery
across CKD stages; extremely preterm may be an
important issue in undiagnosed or late referred CKD and
PE-AKI
SGA (IUGR) <5th or <10th centile for
gestational age
Strictly and inversely related to preterm delivery; SGA and
IUGR are probably related to risk for hypertension,
metabolic syndrome and CKD in adulthood
Malformations Any kind of malformations Malformations are not increased in CKD patients not
treated by teratogen drugs (MMF, mTor inhibitors, ACEi,
and ARBS); exception: diabetic nephropathy (attributed
to diabetes); hereditary diseases, such as PKD, reﬂux
nephropathy, CAKUT may be evident at birth
Hereditary kidney
diseases
Any kind of CKD Several forms of CKD recognize a hereditary pattern or
predisposition; besides PKD, reﬂux and CAKUT,
Alport’s disease, IgA, kidney tubular disorders and
mitochondrial diseases have a genetic background,
usually evident in adulthood and not always clearly
elucidated
CKD –
hypertension
Higher risk of hypertension
and CKD in adulthood
Late maturation of nephrons results in a lower nephron
number in preterm babies; the risks are probably higher in
SGA-IUGR babies than in preterm babies adequate for
gestational age
Other long-term
issues
Developmental disorders Mainly due to prematurity, cerebral hemorrhage or
neonatal sepsis, are not speciﬁc of CKD, but are a threat
in all preterm babies
SLE: systemic lupus erythematosus; AKI: acute kidney injury; GFR: glomerular ﬁltration rate; sCR: serum
creatinine; CKD: chronic kidney disease; LLAC: lupus-like anticoagulant; PE-AKI: preeclampsia acute kidney
injury; SGA: small for gestational age; IUGR: intrauterine growth restriction; MMF: mycophenolate mofetil; mTor:
mechanistic target of rapamycin; ACEi: angiotensin-converting-enzyme inhibitor; ARBS: angiotensin II receptor
blockers; PKD: polycystic kidney disease; CAKUT: congenital anomalies of the kidney and urinary tract; IgA:
immunoglobulin A
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The implications of dialysis initiation may present important clinical and ethical issues;
in highly resourced countries with established prenatal care, the diagnosis of earlier stages
of CKD may lead to more intensive therapy and surveillance (26, 84, 89).
Dialysis and transplantation. Fertility is reduced in ESRD; Australian and European data
suggest a 1:10 ratio from general population to transplantation and from transplantation to
dialysis (1:100 probability as compared with the general population) (45, 83). The ﬁrst
sporadic cases of successful pregnancy on dialysis were described in the 70s, but in the new
millennium, this became an acknowledged real clinical possibility (4, 39, 85).
More than 1,000 pregnancies have been reported in dialysis patients (85). The most
important advance has been the demonstration of a strong relationship between the intensity
(frequency and duration) of the dialysis sessions and positive pregnancy results; thus,
intensifying dialysis up to daily sessions is the current standard of care (4, 39). Changing
attitudes toward counseling women with advanced CKD may be impacted, with the
knowledge of positive outcomes on dialysis for women and their offspring.
Fertility is partly restored after kidney transplantation (11, 22, 23, 80, 104). However,
even in an ideal situation (normal kidney function, no hypertension or proteinuria, at least
2 years after transplantation, without recent rejection episodes), the risk of complications is
higher in women with transplanted kidneys than in the general population. However, if
teratogen drugs are avoided (mycophenolic acid and rapamycine), the outcomes of pregnancy
after kidney transplantation share the same risk factors as CKD (kidney function, hyperten-
sion, and proteinuria) (80).
Experience with pregnancy in patients with a reduced renal function or failing kidney
graft is limited and counseling is still forcedly based on personal experience or indirect
evidence (71, 87). Assisted fertilization techniques are increasingly popular in some settings,
but dedicated studies in CKD patients are few; multiple pregnancies may bear an added risk
in CKD patients, with both native and transplanted kidneys.
Autoimmune diseases, women, and kidney disease
What we know
Autoimmune diseases, such as SLE, RA, and SS, preferentially affect women and are
characterized by systemic inﬂammation leading to target organ dysfunction, including
kidneys. Sex differences in the incidence and severity of these diseases result from a
complex interaction of hormonal, genetic, and epigenetic factors (Table II). The public health
burden of autoimmune diseases, which collectively represent a leading cause of morbidity
and mortality among women throughout adulthood, is substantial (62, 76, 97).
SLE is an autoimmune disease with multiple organ involvement, approximately
affecting ﬁve million people worldwide, disproportionately predominant in women (9:1
female to male ratio) and individuals of non-European ancestry. The highest female
predominance (up to 15:1) is in peak reproductive years. The biology of these differences
has been explored: one explanation is the number of X chromosomes and genetic variants on
the X chromosome (78, 93, 105); another important etiological explanation is the role of
estrogen in SLE. Estrogen’s primary effects are mediated by transcription activity of
the intracellular estrogen receptors, whose proﬁle is altered in T cells from female SLE
patients (63, 86). Cathepsin S protein has recently been identiﬁed as a potential cause of
lupus, triggering the immune system to attack healthy cells, particularly in females (51).
Numerous non-HLA genetic markers may predispose individuals of European, Hispanic, and
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Afro-American ancestry to lupus (52). Susceptibility to SLE during pregnancy is also
multifactorial; one factor being upregulation of IFN-α. Elevated IFN-α, expressed by the
placenta, plays a pathogenic role in SLE, contributing both to the success of placental
reproduction and to increased susceptibility to SLE (69). Regulatory T cells, which may be
the key to cell modulating feto-maternal tolerance, have abnormalities of structure and
function, and may contribute to pregnancy pathology in women with SLE and to
challenges of managing them during pregnancy (99). SLE affects kidneys in about
50% of patients, including glomerular, interstitial, and vascular lesions. Lupus nephritis
is a major risk factor for overall morbidity and mortality in SLE, despite potent therapies
still lead to signiﬁcant impairment of kidney function for many patients (5). Kidney disease
is a critical concern in counseling women with lupus considering pregnancy, with previous
kidney involvement and lower C4 levels conferring high risk of active nephritis occurring
in pregnancy (13). Socioeconomic disparities are also linked to the health of patients with
lupus. Poverty is associated with an increased long-term level of accumulated disease-
associated damage and a 1.67 times increased likelihood of experiencing a clinically
meaningful increase in damage. Frequency of adverse pregnancy outcomes in women with
lupus is twofold higher in black and Hispanic women than in white women. In blacks,
socioeconomic status was a determinant of pregnancy outcomes and a key contributor to
adverse pregnancy outcomes (49, 110).
RA also preferentially affects women (4:1 ratio to men) with the peak incidence at the
age of 45–55, coinciding with the perimenopausal years. This suggests a possible association
between estrogen deﬁciency and disease onset. Female-to-male incidence ratio after age 60
years is approximately 1:1, potentially implicating changes in sex hormones in the develop-
ment of RA, and a pattern of RA symptom improvement or even remission during pregnancy
is well recognized (20, 34, 66). Renal involvement in RA is relatively common and
multifactorial and is a predictor of mortality in RA patients. The risk of CKD is signiﬁcantly
higher in patients with RA than in the general population. The development of CKD may
result from several ongoing processes, including speciﬁc renal involvement associated with
RA (e.g., glomerulonephritis and interstitial nephritis), chronic inﬂammation, comorbidities,
and nephrotoxic anti-rheumatic drugs. The strong association between RA activity and serum
amyloid A protein amyloidosis increases morbidity and is the main cause of ESRD with RA
and nephropathy. Importantly, some of the lifelong and combined RA pharmacotherapy can
lead to various renal side effects (6, 16, 42).
Table II. Sex differences in the incidence and severity of autoimmune diseases
SLE RA SS
Peak incidence Reproductive age Perimenopausal After 50–60 years
Female/male ratio Peak 15:1 Peak 4:1 Peak 14:1
Total 9:1 After 60 years 1:1 Total 3:1
Inﬂuence of estrogen High levels Negative Positive Unknown
Low levels Unknown Negative Negative
SLE: systemic lupus erythematosus; RA: rheumatoid arthritis; SS: systemic scleroderma
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SS predominantly affects women (female-to-male ratios ranging from 3:1 to 14:1), with
the peak incidence in the ﬁfth and sixth decades. Estrogen may play a role in scleroderma
pathogenesis through its stimulatory effect on transforming growth factor-beta 1 receptor and
platelet-derived growth factor receptor (102). Vasculopathy is an important disease-related
manifestation in SS, and the low estrogenic state associated with menopause has been
suggested to aggravate vascular manifestations in affected women (92). SS can also be
complicated by a number of different forms of kidney disease, including scleroderma renal
crisis, which represents a form of malignant hypertension with acute renal failure; or more
commonly ischemic nephropathy leading to slowly progressive CKD, accompanied by
hypertension and albuminuria (49). Normotensive acute renal failure in patients with SS may
be caused by interstitial nephritis or anti-neutrophil cytoplasmic antibody (ANCA) vasculitis,
a separate entity in scleroderma with poor outcome (7, 77, 111).
Women, CKD, and access to renal replacement therapies (RRTs)
What we know
Although RRT, including dialysis and transplantation, is life-sustaining, not all patients
receive RRT. The rate of ESRD treated by RRT differs greatly between countries and regions,
and intricately depends on the economy of a country and healthcare system (24, 93).
Worldwide, only 50% of patients requiring RRT receive treatment (58), and even less in low-
and middle-income countries and regions; in large parts of Sub-Saharan Africa, less than 2%
of ESRD are treated by RRT (73). The equality of access to RRT for women and girls is of
particular concern because, in many societies, they are disadvantaged by discrimination
rooted in sociocultural factors (25, 107).
Sex differences in access to dialysis
At least 2.284 million people may have prematurely died due to lack of access to RRT with
treatment gaps being much larger in low-income countries, with conservative estimates in
Asia and Africa of 1.907 million and 432,000 people not receiving RRT. By 2030, the
estimated number of RRT should be doubled to more than 5.439 million (3.899–7.640
million), with the most growth in Asia [0.968 million to a projected 2.162 million (1.71–3.14
million)] (58). These numbers are derived from an extensive systematic review.
There are few data to compare the gender difference for the treatment gaps. Studies in
Africa show that men were more likely to receive RRT than women (3, 38). In Japan, the
incidence of treated ESRD in females was less than half of that in males (3,287 in males vs.
1,764 women per million population treated) (93); no explanations are given for this ﬁnding.
One US study reports women having signiﬁcantly higher odds ratio of 1.70 for late initiation
of dialysis compared with men (50). Awareness levels of previous kidney disease in women
were reported much lower than in men (2.9%± 1.6% in women vs. 17.9%± 5.9% in men),
which may contribute to later initiation of RRT (17).
Mortality rates are similar in men and women on dialysis, but the incident rates of some
dialysis-associated complications and morbidity are higher in women. A US report of
hospitalizations in 111,653 patients undergoing maintenance hemodialysis describes higher
hospitalization rates in women, and higher risk for 30-day readmissions (2).
In addition, the prevalent use of arteriovenous ﬁstula, which is associated with reduced
mortality, complication, and costs, is lower among female than male hemodialysis patients
(27). This may be due to a number of different factors, including anatomical/surgical issues
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relating to vessel size, timing of referral, and attitudinal differences. This has not been
systematically studied.
Dialysis dose, which is evaluated by Kt/V, may result in underdialysis in women who
have an average smaller volume of urea distribution or total body water than men (21).
Women receiving dialysis have also been reported to have worse clinical parameters
including anemia, nutrition, and quality of life (95). Reasons are not certain.
Sex differences in access to kidney transplantation
Transplantation represents the best form of RRT in patients without contraindications.
Worldwide data describe that women are less likely than men to be kidney transplant
recipients, either from a cadaveric or living donor, but are more likely to serve as living
donors for kidney transplantation (47). Data from different countries, including the US,
France, China, and India, conﬁrm differential kidney transplant rates (lower in women
than men), less likelihood of women being registered on national transplant waiting lists,
and longer time from dialysis initiation to listing. Mothers are more likely to be donors, as
are female spouses (8, 18, 55, 67, 93). Sex inequality also exists in the pediatric
population. A survey from 35 countries, which participated in the European Society for
Pediatric Nephrology/European Renal Association–European Dialysis and Transplant
Association Registry, reported that girls had a lower access to renal transplantation than
boys (40).
Socioeconomic factors undoubtedly play a role in the inequality of transplantation
between sexes, especially in the low- and middle-income countries and regions. Generally,
men provide the major income for their family, which may discourage them to donate
kidneys. Different employment status and incomes between genders may contribute to sex
differences in transplantation, because employment and income status is usually associated
with better healthcare insurance that covers the costs for transplantation. Psychosocial factors
and education of women have been suggested as a contribution to sex disparity. US data
found black women were less likely to want living donor kidney transplantation compared
with men, despite being twice as likely as men to receive unsolicited offers for kidneys. They
were also less likely to have been evaluated for a kidney transplant (33). Other reports
describe disparities in age and sex in access to kidney transplantation, which originate during
pre-referral discussions about kidney transplantation; irrespective of age, women were more
likely not to have had discussions with medical professionals. This result may imply that
there is a need for better clinical guidelines and education for women, their social network,
and their providers (91).
Present and future: What we do not know
Given the data presented above with respect to pregnancy, AKI, autoimmune diseases, CKD,
dialysis and transplantation, there are many unanswered questions. In high-income countries
with increasing maternal age and assisted fertilization, there may be an increase in PE, which
may impact future generations if associated with adverse fetal outcomes. The increase in in
vitro fertilization techniques for those of advanced maternal age may lead to multiple
pregnancies, which may predispose to PE, intrauterine growth restriction, or both. Will this
lead to an increase in CKD and CVD for women in the future?
Due to the high heterogeneity of CKD, we do not know if and how pregnancy outcomes
are modulated by the different nephropathies, as besides the most common ones, such as
IgA or lupus nephropathy, diabetic nephropathy, and reﬂux nephropathy, evidence is
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scant (10, 32, 79, 94, 109, 114). How should we deﬁne preconception risks of pregnancy with
respect to current proteinuria cut offs? Indications on when to start dialysis in pregnancy are
not well established, nor is the speciﬁc role of frequency and duration. In those with kidney
transplants, given the changing expanded donor policies, higher age at transplantation, and
reduced fertility in older women, there may be changes in attitudes toward pregnancy with
less than optimal kidney function (23, 104). How this will impact short- and long-term
outcomes of mothers and their babies is not clear.
Teen pregnancies are very common in some parts of the world, and are often associated
with low income and cultural levels. The uneven legal rules for assisted fertilization and the
lack of systematic assessment of the kidney function point to the need for further research.
Despite elegant demonstrations for the role of sex hormones in vascular health and
immunoregulation, the striking predominance in females of SLE, RA, and SS remains
unexplained relative to other systemic diseases, such as ANCA vasculitis and hemolytic-
uremic syndrome. Note that thrombotic thrombocytopenic purpura has a higher incidence in
women, although this is likely due to the association with other conditions more common in
women. The incidence of kidney involvement in SLE during pregnancy and similarities/
differences in those with PE have not been well studied. The role of different medications and
responses to medications for autoimmune diseases relative to sex has also not been well
studied.
More attention to similarities between conditions, the importance of sex hormones in
inﬂammation, immune-modulation, and vascular health may lead to important insights and
clinical breakthroughs over time. If women are more likely to be living donors, at differential
ages, does this impact both CVD risk, and risk for ESKD?: have we studied this well enough
in the current era, with modern diagnostic criteria for CKD and sophisticated tools to
understand renal reserve? Are the additional exposures that women have after living donation
compounded by hormonal changes on vasculature as they age? And are the risks of CKD and
PE increased in the younger female kidney living donor?
In the context of speciﬁc therapies for the treatment or delay of CKD progression, do we
know if there are sex differences in therapeutic responses to ACEi/ARB? Should we look at
dose ﬁnding/adjustments by sex? If vascular and immune biology is impacted by sex
hormones as described earlier, do we know the impact of various therapies by level or ratio of
sex hormones? In low–middle income countries, how does changing economic and social
cultures impact women’s health, and what is the nutritional impact on CKD of increasing
predominance of obesity, diabetes, and hypertension?
Summary
Women have unique risks for kidney diseases: kidney diseases, as well as issues related to
access to care, have a profound impact on both the current and next generations. Advocating
for improved access to care for women is critical to maintain the health of families,
communities, and populations.
Focused studies on the unique contribution of sex hormones, or the interaction of sex
hormones and other physiology, are important to improve our understanding of the
progression of kidney diseases. Immunological conditions, such as pregnancy (viewed as
a state of tolerance to non-self) as well as SLE and other autoimmune and systemic conditions
common in women, better studied may also lead to breakthroughs in understanding and care
paradigms.
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There is a clear need for higher awareness, timely diagnosis, and proper follow-up of
CKD in pregnancy. In turn, pregnancy may also be a valuable occasion for early diagnosis of
CKD, allowing planning of therapeutic interventions.
On this occasion, World Kidney Day and the International Women’s Day 2018 are
commemorated on the same day, offering us the opportunity to highlight the importance of
women’s health and particularly their kidney health. On its 13th anniversary, World Kidney
Day promotes affordable and equitable access to health education, healthcare, and prevention
for all women and girls in the world.
The coincidence of World Kidney Day and International Women’s Day offers an
opportunity to develop and deﬁne best practices and future research agendas, and ultimately,
to optimize the outcomes of all people living with or at risk for kidney disease.
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